|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Debt securities, available for sale, current | ||||||||||||||||||||
| Accrued interest receivable on investment securities | ||||||||||||||||||||
| Advances and deposits on clinical programs and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Property and equipment (at cost, less accumulated depreciation and amortization) | ||||||||||||||||||||
| Other assets: | ||||||||||||||||||||
| Deferred income tax asset | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Operating lease right-of-use assets, net | ||||||||||||||||||||
| Deposits and other assets | ||||||||||||||||||||
| Total other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable – trade | ||||||||||||||||||||
| Other accrued liabilities | ||||||||||||||||||||
| Note payable - Note A – current portion | ||||||||||||||||||||
| Operating lease liability - current portion | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Note payable | ||||||||||||||||||||
| Related Party A | ||||||||||||||||||||
| Related Party B | ||||||||||||||||||||
| Operating lease liability - non-current portion | ||||||||||||||||||||
| Derivative liability associated with redemption feature of Note A | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Stockholders’ equity: | ||||||||||||||||||||
| Preferred stock - $0.01 par value (100,000 shares authorized; 250 shares issued and outstanding at June 30, 2026, and no shares issued or outstanding at December 31, 2025) | ||||||||||||||||||||
| Additional paid-in capital - preferred stock | ||||||||||||||||||||
| Common stock - $0.01 par value (350,000,000 shares authorized; 4,665,662 and 3,419,652 shares issued at June 30, 2026 and December 31, 2025, respectively; and 4,665,660 and 3,419,650 shares outstanding at June 30, 2026 and December 31, 2025, respectively) | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders’ equity before treasury stock | ||||||||||||||||||||
| Treasury stock, at cost (2 shares at June 30, 2026 and December 31, 2025) | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities and stockholders’ equity | ||||||||||||||||||||
Loading...
